Table 1: International guidelines for the management of H. pylori infection.
CLA-R: clarithromycin-resistant; CLA-TT: clarithromycin-containing triple therapy; BQT: bismuth-containing quadruple therapy; LEV-T: levofloxacin-containing triple therapy; ST: sequential therapy; CT: concomitant therapy.
Guidelines 2016
Canada		 2012
Europe		 2009
Asia-Pacific Region		 2007
USA
First-line Guided by antimicrobial
susceptibility testing
BQT, 14 days
CT, 14 days		 Low CLA-R
CLA-TT, 7-14 days
High CLA-R
BQT, 10-14 days		 CLA-TT, 7-14 days CLA-TT, 10-14 days
BQT, 10-14 days
Alternative Low CLA-R
CLA-TT, 14 days		 Low CLA-R
BQT, 10-14 days
High CLA-R
ST, 10 days/CT		 BQT, 7-14 days
ST, 10 days
(need more data)		 ST, 10 days
(need more data
Second-line BQT, 14 days
LEV-T, 14 days		 Low CLA-R
BQT, 10-14 days
LEV-T, 10 days
High CLA-R
LEV-T, 10 days		 BQT, 7-14 days
LEV-T, 10 days
RIF-T, 7-10 days		 BQT, 10-14 days
LEV-T, 10 days
Third-line Guided by antimicrobial susceptibility testing